Quick Answer
Peptide supply is tighter in late 2026, and lead times are longer and harder to predict. Some of the causes are documented: since September 2025 the US has held GLP-1 drug ingredients from unchecked foreign makers at the border, US customs has seized thousands of misdeclared peptide parcels from China, US lawmakers and state attorneys general have pressed for more action on Chinese suppliers, and Eli Lilly has sued sellers of its unapproved obesity drug and asked shipping carriers to help stop such sales. Other causes are reported by suppliers but not confirmed by any official source, including more factory inspections in Shenzhen and other hubs and freight forwarders refusing or delaying peptide freight. For researchers, this means planning further ahead, checking identity and purity with independent tests, and valuing stock already held in the destination country.
Our earlier report on mislabelled and substituted lots from Chinese manufacturers looked at what arrives in the vial. This article looks at the route the vial takes to get there: the factory, the freight forwarder, the border and the regulator. Since the end of 2025, pressure on each of those steps has grown, and suppliers across the research market describe longer and less predictable lead times as a result.
We separate three things below: what is documented by a government, regulator, court filing or company announcement; what suppliers report but nobody official has confirmed; and our own view of where this is heading. Nothing here is medical advice or advice on the law.
What Is Documented
The table lists the main documented events in date order. Each one is explained, with its source, in the sections that follow.
| Date | What happened |
|---|---|
| 4 Jan 2024 | Eli Lilly launches LillyDirect, selling some of its medicines directly to US patients |
| 5 Mar 2025 | Novo Nordisk launches NovoCare Pharmacy, its own direct-to-patient channel |
| 5 Sep 2025 | US FDA launches a green list of checked foreign GLP-1 ingredient makers; others can be held at the border |
| Dec 2025 to Mar 2026 | US customs in Cincinnati seizes about 5,000 misdeclared peptide parcels from a shipper in China |
| 18 Dec 2025 | BIOSECURE Act becomes US law, aimed at biotechnology companies linked to foreign adversaries |
| 14 Jan 2026 | Senior US House member writes to three Chinese biotech firms about GLP-1 manufacturing and exports |
| 27 Jan 2026 | China issues revised national drug regulations, in force from 15 May 2026 |
| 5 Feb 2026 | US government launches TrumpRx, linking buyers to drug makers' direct sales |
| 6 Feb 2026 | FDA says it will restrict GLP-1 ingredients meant for mass-marketed compounded products |
| 5 Mar 2026 | Lilly launches Employer Connect, a direct route to US employers |
| 2 Apr 2026 | US tariffs announced on imported patented medicines and their active ingredients |
| Apr 2026 | China's medicines regulator tightens rules for contract drug manufacturers |
| 1 May 2026 | FDA warning letter to a Chinese GLP-1 ingredient maker over relabelled product |
| 28 May 2026 | UK MHRA makes its largest ever seizure of unlicensed weight-loss medicines |
| 24 Jul 2026 | New US entry process for low-value mail takes effect |
| 12 Aug 2026 | Lilly files six lawsuits against US sellers and asks shipping carriers to help stop sales |
| 21 Sep 2026 | 20 US state attorneys general ask for national security action on Chinese GLP-1 ingredients |
| 9 Oct 2026 | Latest version of FDA Import Alert 66-80 published |
US checks on imported GLP-1 ingredients
On 5 September 2025 the US FDA launched a green list of foreign makers of GLP-1 drug ingredients that it had inspected or evaluated and found to appear compliant (FDA, September 2025). Under Import Alert 66-80, ingredients from makers not on the list can be held at the US border without physical examination. The FDA says that of 48 GLP-1 ingredient sites it evaluated, 21% were non-compliant, and it describes a pattern of sites that register, offer ingredients for export, refuse records requests and then deregister. The alert has been revised during 2026, and the version on the FDA site carries a publication date of 9 October 2026 (FDA Import Alert 66-80).
The FDA has acted on the list. In a warning letter dated 1 May 2026, it said a Chinese ingredient maker on the green list had bought a GLP-1 ingredient from a facility that was not on the list, relabelled it as its own and shipped it to the US. The firm had already been removed from the list in February 2026 (BioSpace, May 2026). The agency has also turned to the US end of the chain: on 6 February 2026 it said it would restrict GLP-1 ingredients intended for mass-marketed compounded products and act against misleading advertising (AJMC, February 2026).
Seizures at the border
US Customs and Border Protection says officers at the Port of Cincinnati seized shipments from a shipper in China between December 2025 and 25 March 2026: more than 300 master cartons, each holding about 15 smaller parcels already labelled for individual US recipients, or roughly 5,000 packages in total. CBP says the shipments were declared as other goods and contained peptides, particularly active ingredients for GLP-1 weight-loss drugs (CBP, 31 March 2026).
In the UK, the MHRA reported its largest ever seizure of unlicensed weight-loss medicines, including peptide products, after a raid on a rural estate near Northampton on 28 May 2026 (MHRA, May 2026).
Political and trade pressure on Chinese suppliers
On 14 January 2026 the ranking member of the US House Select Committee on the Chinese Communist Party wrote to three Chinese biotech firms asking about their manufacturing, labelling and export of GLP-1 drugs and ingredients (House Select Committee, January 2026). On 21 September 2026 Oklahoma's attorney general and 19 other state attorneys general wrote to the US Secretary of State asking the National Security Council to act on GLP-1 ingredients from Chinese businesses, arguing that gaps around the green list are being exploited (Oklahoma Attorney General, September 2026).
Wider US trade policy points the same way. The BIOSECURE Act became law on 18 December 2025 as part of the 2026 US defence budget law. It will stop US federal agencies buying biotechnology equipment or services from designated biotechnology companies of concern; the list is due by December 2026 and the bans may not apply until 2027 (Arnold & Porter, December 2025). A US proclamation of 2 April 2026 set a standard tariff of 100% on imported patented medicines and their active ingredients, applied from 31 July 2026 for named companies and from 29 September 2026 for all other importers. Generic medicines are excluded, qualifying imports from the EU and Japan pay 15%, and UK imports pay 0% under a US and UK agreement (Mohawk Global, August 2026). The US has also ended duty-free entry for low-value parcels: an executive order of 30 July 2025 suspended it for all countries, and from 24 July 2026 low-value mail has to go through a new postal entry process (CBP, July 2026).
China's own rule changes
China's State Council issued revised implementing regulations for its national drug law on 27 January 2026, in force from 15 May 2026. They put more responsibility for quality, across a medicine's whole life, on the companies that hold medicine licences (Morgan Lewis, February 2026). In April 2026 China's medicines regulator, the NMPA, set tighter rules for contract drug manufacturers, including at least yearly on-site oversight of key validation work for high-risk products such as sterile drugs, and asked provincial regulators to push for full self-inspections (RAPS, April 2026).
Neither document mentions peptide exports or Shenzhen, and both apply to licensed medicine production in general. They are the closest official sources we found to the inspection reports described in the next section, but they do not confirm them.
What drug makers have done
On 12 August 2026 Eli Lilly filed six lawsuits against US businesses it says sold unapproved versions of its investigational obesity drug: four online sellers that advertised their products for research use, a medical spa and a compounding pharmacy (CBS News, August 2026). Lilly alleges that the research-use marketing was aimed at people who wanted the drug for themselves. It also called on social media and e-commerce platforms, credit card companies, payment processors and shipping and logistics carriers to help stop the sales (Straight Arrow News, August 2026). These are allegations, and the courts have not ruled on them.
Drug makers have also built direct routes to patients for their approved medicines. Lilly launched LillyDirect in January 2024, with home delivery through third-party online pharmacies and access to independent telehealth providers (Lilly, January 2024). Novo Nordisk followed with NovoCare Pharmacy in March 2025 (Healio, March 2025). In February 2026 the US government launched TrumpRx, a website that links buyers to drug makers' own direct-to-consumer sites or gives them a coupon for a pharmacy (CNN, February 2026). In March 2026 Lilly added Employer Connect, which lets US employers offer its obesity medicine through a dedicated pharmacy network (Pharmaceutical Executive, March 2026).
What Suppliers Report, Not Yet Confirmed
The points below come from suppliers, freight agents and trade discussion in the research market, including reports from our own suppliers in October 2026. We could not confirm any of them against an official source, and we have not seen reliable published figures, so we give none.
- More factory inspections. Suppliers describe more frequent inspections of peptide manufacturers in Shenzhen and other manufacturing hubs, with some sites pausing output while they are inspected. We found no official notice of a peptide-specific inspection campaign; the closest official sources are the general rule changes above.
- Freight forwarders clamping down. Forwarders are reported to be refusing peptide freight, holding consignments for extra paperwork, returning parcels after accepting them, or closing routes at short notice. We found no published forwarder or carrier policy on peptides. Lilly's public call on shipping and logistics carriers is documented; whether any carrier changed its policy as a result is not.
- Longer lead times. Suppliers describe longer and less predictable times from order to dispatch, and from dispatch to arrival, especially on international routes.
- Shutdown rumours. A claim circulated in September 2026 that peptide shipments from China would stop from about 22 September for two to four months. We found no official rule behind it. The dates did overlap with China's Mid-Autumn Festival (25 to 27 September 2026) and National Day holiday (1 to 7 October 2026), when factories and freight services usually slow down (State Council notice, November 2025).
Until an official source confirms them, treat these as signals rather than facts. We will update this article if an official source confirms or rules them out.
What This Means for Researchers
- Plan for longer lead times. Allow more time for anything shipped internationally, and extra time around Chinese public holidays and customs checks.
- Verify identity and purity. When supply is tight, the risk of substituted or out-of-spec material rises, as our earlier report describes. Independent HPLC for purity and mass spectrometry for identity are the checks that matter. Our guide on how to verify a peptide COA explains what to look for, and examples of independent lab tests are in our library.
- Value stock already in the destination country. Material that has already cleared import is not exposed to the same freight and customs delays at the time of order. For UK researchers, that means stock already held in the UK.
Our View: Access Is Spreading Out
This section is our opinion, not established fact.
We think the supply pressure described above is part of a wider change: access to these medicines, and to research compounds, is spreading away from a few traditional channels. Some people call this the decentralisation of healthcare. On the medicines side, drug makers now sell directly to patients and employers, the US government runs a direct-purchase website, and telehealth companies prescribe online. On the research side, compounds are bought by a wider and more independent group of research buyers than a few years ago. We expect this shift to continue.
We also expect the regulatory pressure that comes with it to continue. As access spreads out, regulators, customs agencies and drug makers are acting at more points along the chain: ingredient makers, freight carriers, payment companies, telehealth firms and sellers. Eli Lilly is the most visible company on both sides of this change: it has built direct channels for its approved medicines, and it is taking legal action against sellers of its unapproved one. We read the inspection and freight reports as part of the same pattern, but we cannot show a direct link between any company's actions and any specific delay.
To be clear: research peptides are sold for laboratory research only. They are not medicines, they are not for personal use, and they are not a substitute for anything a doctor prescribes. Nothing in this article says that any product is approved or permitted for sale or use in any country.
Bottom Line
Peptide supply in late 2026 is tighter for documented reasons, mainly US action on GLP-1 ingredients from China, more border seizures and wider US trade restrictions, and for reported reasons that are not yet confirmed, mainly factory inspections and caution among freight forwarders. For researchers the practical response is the same either way: order earlier, insist on independent identity and purity data, and value stock that has already arrived where you are.
References
- AJMC (2026). FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads. AJMC, 9 February 2026. ajmc.com
- Arnold & Porter (2025). The BIOSECURE Act Becomes Law in the United States. Arnold & Porter advisory, 23 December 2025. arnoldporter.com
- BioSpace (2026). FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions. BioSpace, 20 May 2026. biospace.com
- CBS News (2026). Eli Lilly takes aim at illicit market for its experimental weight-loss drug. CBS News, 12 August 2026. cbsnews.com
- CNN (2026). TrumpRx launches, but it's unclear if it will lower drug prices for most patients. Republished by ABC7 Los Angeles, 6 February 2026. abc7.com
- Eli Lilly and Company (2024). Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect. Press release, 4 January 2024, via BioSpace. biospace.com
- Healio (2025). NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain. Healio Endocrinology, 7 March 2025. healio.com
- Medicines and Healthcare products Regulatory Agency (2026). Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. GOV.UK, 29 May 2026. gov.uk
- Mohawk Global (2026). Section 232 Tariffs on Patented Pharmaceutical Imports Take Effect. Mohawk Global, 7 August 2026. mohawkglobal.com
- Morgan Lewis (2026). Navigating China's New 2026 Implementing Regulations of the Drug Administration Law. Morgan Lewis LawFlash, 10 February 2026. morganlewis.com
- Office of the Oklahoma Attorney General (2026). Drummond alerts National Security Council to exploitation of FDA approved drugs by Chinese businesses. News release, 21 September 2026. oklahoma.gov
- Pharmaceutical Executive (2026). Eli Lilly Launches Employer Connect Platform Offering Obesity Coverage Options. Pharmaceutical Executive, 5 March 2026. pharmexec.com
- RAPS (2026). Asia-Pacific Roundup: China's NMPA strengthens supervision and responsibilities of contract manufacturers. Regulatory Affairs Professionals Society, April 2026. raps.org
- State Council General Office of the People's Republic of China (2025). Notice on the arrangement of some public holidays in 2026. Xinhua, 4 November 2025. news.cn
- Straight Arrow News (2026). Eli Lilly sues six companies for selling illegal versions of groundbreaking weight-loss drug. Straight Arrow News, 12 August 2026. san.com
- US Customs and Border Protection (2026). Cincinnati CBP foils scheme to smuggle over 5,000 unapproved peptides into the U.S. News release, 31 March 2026. cbp.gov
- US Customs and Border Protection (2026). CSMS # 69183472: Updated Global Guidance for International Mail. 8 July 2026. content.govdelivery.com
- US Food and Drug Administration (2025). FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients. Press announcement, 5 September 2025. fda.gov
- US Food and Drug Administration (2026). Import Alert 66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances. Published 9 October 2026. accessdata.fda.gov
- US House Select Committee on the CCP, Democrats (2026). Krishnamoorthi Sends Letters to Chinese Biotech Firms Regarding Illicit and Potentially Dangerous Counterfeit GLP-1 Manufacturing Threatening U.S. Drug Supply. Press release, 14 January 2026. house.gov